Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Repare Therapeutics Inc. (RPTX : NSDQ)

• Company Description    Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare Therapeutics Inc. is based in St-Laurent, Canada. Number of Employees: 152

• Price / Volume Information    Yesterday's Closing Price: $8.45 Daily Weekly Monthly 20 Day Moving Average: 205,874 shares Shares Outstanding: 41.89 (millions) Market Capitalization: $354.00 (millions) Beta: 0.89 52 Week High: $35.75 52 Week Low: $8.07 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.09% -19.01% 12 Week -44.92% -39.45% Year To Date -59.93% -50.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7210 Frederick-Banting Suite 100 - St-Laurent,A8 H4S 2A1 CAN ph: 857-412-7018 fax: - investor@reparerx.com http://www.reparerx.com

• General Corporate Information    Officers Lloyd M. Segal - President and Chief Executive Officer Thomas Civik - Chairman Steve Forte - Executive Vice President and Chief Financial Offic Jerel Davis - Director Todd Foley - Director Peer Information Repare Therapeutics Inc. (CORR.) Repare Therapeutics Inc. (RSPI) Repare Therapeutics Inc. (CGXP) Repare Therapeutics Inc. (BGEN) Repare Therapeutics Inc. (GTBP) Repare Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 760273102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 41.89 Most Recent Split Date: (:1) Beta: 0.89 Market Capitalization: $354.00 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.86 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.37 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.37 Price/Cash Flow: - Price / Sales: 45.14 EPS Growth vs. Year Ago Period: -43.10% vs. Previous Quarter: -18.57% Sales Growth vs. Year Ago Period: 145.78% vs. Previous Quarter: -94.07% ROE 03/31/22 - -47.60 12/31/21 - -41.95 09/30/21 - -36.89 ROA 03/31/22 - -36.38 12/31/21 - -32.30 09/30/21 - -28.61 Current Ratio 03/31/22 - 9.37 12/31/21 - 10.02 09/30/21 - 11.98 Quick Ratio 03/31/22 - - 12/31/21 - 10.01 09/30/21 - 11.98 Operating Margin 03/31/22 - -1,533.38 12/31/21 - -1,406.68 09/30/21 - -10,941.61 Net Margin 03/31/22 - -1,533.38 12/31/21 - -1,406.68 09/30/21 - -10,941.61 Pre-Tax Margin 03/31/22 - -1,552.63 12/31/21 - -1,428.76 09/30/21 - -11,270.51 Book Value 03/31/22 - 6.17 12/31/21 - 6.91 09/30/21 - 5.88 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©